Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Final Thoughts and Clinical Pearls for Treating SCLC

October 31st 2025

Panelists discuss how the next 3 to 5 years will likely see T-cell engagers moving into earlier treatment lines, potential ADCs replacing chemotherapy in first-line therapy, and the critical need for better biomarker testing to optimize treatment sequencing and patient selection in an increasingly complex therapeutic landscape.

OncLive’s October Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

October 31st 2025

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD

October 30th 2025

Drs Hanhan, Bauer, and NeMoyer discuss the ins and outs of lung cancer diagnosis, surgical management, and evolving treatment paradigms.

Advances in EGFR+, HER2-Mutant, and CNS-Involved NSCLC Dominate Discussion After ESMO 2025

October 30th 2025

Experts highlight pivotal data in EGFR- and HER2-mutant NSCLC from the 2025 ESMO Congress, including updates on ADCs, TKIs, and real-world outcomes in LMD.

IO102-IO103 Plus Pembrolizumab Demonstrates Favorable Activity in PD-L1–High HNSCC and NSCLC

October 29th 2025

Jonathan Riess, MD, discusses data for IO102-IO103 plus pembrolizumab in advanced HSNCC and NSCLC with high PD-L1 expression.

Osimertinib Plus Chemo Outperforms Single-Agent Osimertinib Regardless of Prognostic Factors in EGFR+ NSCLC

October 29th 2025

Pasi A. Jänne, MD, PhD, shares data confirming an OS benefit with osimertinib plus chemotherapy regardless of baseline prognostic factors in EGFR-mutant NSCLC.

Dr Lee on the Role of SABR in Non–Small Cell Lung Cancer Management

October 28th 2025

Percy Lee, MD, discussed the use of SABR within the larger radiation therapy paradigm for the management of non–small cell lung cancer.

Defining Surgical Eligibility in N2 Early-Stage NSCLC

October 28th 2025

Panelists discuss how multistation N2 disease is no longer an absolute contraindication to surgery, with treatment decisions based on biology rather than just nodal station number, though bulky vs invasive disease characteristics matter.

Optimizing Care in Unresectable Stage III NSCLC: Chemoradiation and Immunotherapy

October 28th 2025

Panelists discuss how concurrent chemoradiation remains standard, when possible, with sequential approaches for frail patients, and consolidation immunotherapy recommended regardless of the initial radiation approach.

Five Under 5: Top Oncology Videos for the Week of 10/19

October 26th 2025

The top 5 OncLive TV videos of the week cover insights in breast cancer and lung cancer.

Chemotherapy Combination Boosts Overall Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

October 24th 2025

Osimertinib plus chemotherapy resulted in a significant and improvement in OS in newly diagnosed EGFR-mutated advanced NSCLC vs osimertinib alone.

Exploring Investigational Approaches Including Cellular Therapy

October 24th 2025

Panelists discuss how emerging therapies including DLL3-targeted ADCs, trispecific T-cell engagers, CAR T cells, and radioligand therapies represent promising approaches that may offer single-dose treatments or enhanced efficacy, though more data on durability and optimal sequencing are needed.

Key Efficacy and Safety Insights From Emerging Therapies in SCLC

October 24th 2025

Panelists discuss how antibody-drug conjugates targeting B7-H3 show impressive response rates compared to historical controls, while T-cell engagers remain the priority for second-line therapy due to their demonstrated durability, though patient preferences and contraindications may influence individual treatment decisions.

Vopimetostat Demonstrates Early Evidence of Efficacy in MTAP-Deleted Solid Tumors

October 23rd 2025

Vopimetostat elicited responses and was considered tolerable in patients with MTAP-deleted solid tumors, including pancreatic and lung cancers.

HLX43 Nets FDA Orphan Drug Designation in Thymic Epithelial Tumors

October 21st 2025

The FDA granted orphan drug designation to HLX43 for thymic epithelial tumors

Dr Lee on the Optimal Patient Population to Receive Proton Therapy for Advanced NSCLC

October 21st 2025

Percy Lee, MD, discusses different radiation modalities for patients with NSCLC, the increasing complexity of reirradiation, and the strategic use of SABR.

Balancing Surgery, Radiation, and Targeted Therapy in Early-Stage NSCLC

October 21st 2025

Panelists discuss how treatment selection for early-stage disease depends on lymph node metastasis risk, with SBRT considered for very low-risk peripheral tumors and surgery preferred when staging information is needed.

Defining Surgical Candidacy in Newly Diagnosed Early-Stage NSCLC

October 21st 2025

Panelists discuss how most patients with early-stage disease who would benefit from systemic therapy should receive neoadjuvant treatment, with direct surgery reserved mainly for those with medical contraindications to immunotherapy.

Frontline EIK1001 Plus Chemoimmunotherapy Stimulates Antitumor Activity in Advanced NSCLC

October 20th 2025

EIK1001 plus pembrolizumab and chemo showed a 64% ORR and manageable safety in first-line stage IV NSCLC, per phase 2 TeLuRide-005 data.

Adjuvant Alectinib Impresses in Updated ALINA Results for ALK+ NSCLC

October 20th 2025

Long-term data from the ALINA trail continued to support the use of adjuvant alectinib in resected, ALK-positive, early stage non–small cell lung cancer.